Sanofi and ImmuNext, Inc., have announced an agreement focused on the development of a novel antibody with the potential to treat a range of autoimmune diseases including Lupus and Multiple Sclerosis. Under the terms of the agreement, ImmuNext will grant
The U.S. Army's decision to transfer a Zika vaccine candidate's license to development partner Sanofi has prompted protest from a nonprofit worried about the legality of the plan and the product's future pricing.